October 10, 2014 -- ContraFect Corporation, a New York biotech, and China’s National Institute for Viral Disease Control and Prevention, China CDC (IVDC) formed a collaboration to advance ContraFect’s universal treatment for flu. CF-404, currently in pre-clinical development, is comprised of three fully human monoclonal antibodies. In animal models, using a low dose, it provided protection against all human strains of flu, including pandemic strains. The IVDC will conduct tests of CF-404 on China flu strains. Financial details were not disclosed. More details....
Help employers find you! Check out all the jobs and post your resume.
